Physiomics PLC Physiomics participates at NIHR event
03 Mayo 2019 - 06:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
03 May 2019
3(rd) May 2019
Physiomics plc
("Physiomics") or ("the Company")
Physiomics participates at NIHR event
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, yesterday participated in the "SME Dragon's
Den" event jointly organised by the National Institute for Health
Research ("NIHR") Biomedical Research Centre at The Royal Marsden
NHS Foundation Trust, the Institute of Cancer Research and
DigitalHealth London Accelerator.
Dr Claire Villette and Dr Jim Millen presented for 5 minutes and
were then grilled by a panel of over 15 UK-based experts in the
field of oncology as well as by patient representatives. The
presentation was well-received and the questioning lively and
informative. There were no formal "winners" at this event and the
prize was not cash but rather contact and engagement with some of
the country's leading oncology clinicians and researchers.
Physiomics will follow up with key participants with a view to
garnering feedback, forming partnerships and accessing further data
for the purposes of developing and validating its personalised
oncology tools.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (NOMAD)
Katy Mitchell
James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
This is an RNS Reach
About Physiomics
Physiomics plc (AIM: PYC) is a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry. The Company's Virtual Tumour(TM) technology
uses computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Physiomics' technologies have been confirmed by over
70 projects, involving over 30 targets and 60 drugs, and has worked
with clients such as Merck KGaA, Merck & Co, Bayer and
Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUOVRRKOAVRAR
(END) Dow Jones Newswires
May 03, 2019 07:00 ET (11:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024